Aeterna Zentaris to Announce Third Quarter 2018 Financial and Operating Results on November 6, 2018
01 November 2018 - 7:05AM
Aeterna Zentaris Inc. (NASDAQ:AEZS) (TSX: AEZS)
will announce its third quarter 2018 financial and operating
results after market close on Tuesday, November 6, 2018. The
Company will host a conference call to discuss these results on
Wednesday, November 7, 2018 at 8:30 a.m. Eastern Time.
Participants may access the conference call by telephone using
the following numbers:
- Toll-Free: 877-407-8029, Confirmation #13684540
- Toll: 201-689-8029, Confirmation # 13684540
A replay will also be available on the Company’s website for a
period of 30 days.
About Aeterna Zentaris Inc.
Aeterna Zentaris Inc. is a specialty biopharmaceutical company
focused on developing and commercializing, principally through
out-licensing arrangements, Macrilen™ (macimorelin), an oral
ghrelin receptor agonist, to be administered in the diagnosis of
patients with adult growth hormone deficiency. Aeterna
Zentaris has entered into a license and assignment agreement with a
wholly-owned subsidiary of Strongbridge Biopharma plc to carry out
development, manufacturing, registration and commercialization of
Macrilen™ (macimorelin) in the United States and Canada. For more
information, visit www.zentaris.com.
Contact:
Leslie AuldChief Financial OfficerAeterna Zentaris
Inc.IR@aezsinc.com843-900-3201
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From Apr 2024 to May 2024
Aeterna Zentaris (NASDAQ:AEZS)
Historical Stock Chart
From May 2023 to May 2024